{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:00:46Z","timestamp":1791644446766,"version":"4.3.4"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Human adenovirus type 55 (HAdV55) has a re-emerged as pathogen causing an acute respiratory disease presenting as a severe lower respiratory illness that can cause death. To date, there is no HAdV55 vaccine or treatment available for general use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Herein, a monoclonal antibody specific for HAdV55, mAb 9-8, was isolated from an scFv-phage display library derived from mice immunized with the purified inactived-HAdV55 virions. By using ELISA and a virus micro-neutralization assay, we evaluated the binding and neutralizing activity of mAb 9-8 following humanization. Western blotting analysis and antigen-antibody molecular docking analysis were used to identify the antigenic epitopes that the humanized monoclonal antibody 9-8-h2 recognized. After that, their thermal stability was determined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>MAb 9-8 showed potent neutralization activity against HAdV55. After humanization, the humanized neutralizing monoclonal antibody (9-8-h2) was identified to neutralize HAdV55 infection with an IC50 of 0.6050 nM. The mAb 9-8-h2 recognized HAdV55 and HAdV7 virus particles, but not HAdV4 particles. Although mAb 9-8-h2 could recognize HAdV7, it could not neutralize HAdV7. Furthermore, mAb 9-8-h2 recognized a conformational neutralization epitope of the fiber protein and the crucial amino acid residues (Arg 288, Asp 157, and Asn 200) were identified. MAb 9-8-h2 also showed favorable general physicochemical properties, including good thermostability and pH stability.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Overall, mAb 9-8-h2 might be a promising molecule for the prevention and treatment of HAdV55.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1132822","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T05:32:11Z","timestamp":1678944731000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["A humanized anti-human adenovirus 55 monoclonal antibody with good neutralization ability"],"prefix":"10.3389","volume":"14","author":[{"given":"Lei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiansheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzhou","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujia","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/v7102896","article-title":"Identification and application of neutralizing epitopes of human adenovirus type 55 hexon protein","volume":"7","author":"Tian","year":"2015","journal-title":"Viruses"},{"key":"B2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12985-019-1185-x","article-title":"Human adenovirus among hospitalized children with respiratory tract infections in Beijing, China 2017-2018","volume":"16","author":"Yao","year":"2019","journal-title":"Virol J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.virs.2022.06.006","article-title":"Seroprevalence of neutralizing antibodies against adenovirus type 26 and 35 in healthy populations from guangdong and Shandong provinces, China","volume":"37","author":"Yi","year":"2022","journal-title":"Virol Sin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.688661","article-title":"Molecular characteristics of human adenovirus type 3 circulating in parts of China during 2014-2018","volume":"12","author":"Duan","year":"2021","journal-title":"Front Microbiol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.589","article-title":"Clinical features and treatment of adenovirus infections","volume":"18","author":"Lenaerts","year":"2008","journal-title":"Rev Med Virol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2018.03.002","article-title":"Hexon and fiber of adenovirus type 14 and 55 are major targets of neutralizing antibody but only fiber-specific antibody contributes to cross-neutralizing activity","volume":"518","author":"Feng","year":"2018","journal-title":"Virology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2014.06.019","article-title":"An outbreak of acute respiratory disease in China caused by human adenovirus type B55 in a physical training facility","volume":"28","author":"Li","year":"2014","journal-title":"Int J Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121375","article-title":"Adenoviruses associated with acute respiratory diseases reported in Beijing from 2011 to 2013","volume":"10","author":"Chen","year":"2015","journal-title":"PloS One"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12457","article-title":"A cluster of adenovirus type B55 infection in a neurosurgical inpatient department of a general hospital in guangdong, China","volume":"11","author":"Yi","year":"2017","journal-title":"Influenza Other Respir Viruses"},{"key":"B10","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1186\/s12879-020-05258-2","article-title":"An outbreak of acute respiratory infection at a training base in Beijing, China due to human adenovirus type B55","volume":"20","author":"Lu","year":"2020","journal-title":"BMC Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12232","article-title":"Epidemiology of human adenovirus and molecular characterization of human adenovirus 55 in China 2009-2012","volume":"8","author":"Lu","year":"2014","journal-title":"Influenza Other Respir Viruses"},{"key":"B12","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nri.2017.148","article-title":"Passive immunotherapy of viral infections: 'super-antibodies' enter the fray","volume":"18","author":"Walker","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2174\/1389201020666190809112704","article-title":"Antibody therapy for the control of viral diseases: An update","volume":"20","author":"Dibo","year":"2019","journal-title":"Curr Pharm Biotechnol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.01.025","article-title":"Monoclonal antibodies for prophylactic and therapeutic use against viral infections","volume":"31","author":"Both","year":"2013","journal-title":"Vaccine"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01452-3","article-title":"REGN-EB3: First approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22073703","article-title":"Passive immunoprophylaxis against respiratory syncytial virus in children: Where are we now","volume":"22","author":"Rocca","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2012.12.014","article-title":"Characteristics of neutralizing antibodies to adenovirus capsid proteins in human and animal sera","volume":"437","author":"Yu","year":"2013","journal-title":"Virology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2009.11.006","article-title":"Adenovirus transport via direct interaction of cytoplasmic dynein with the viral capsid hexon subunit","volume":"6","author":"Bremner","year":"2009","journal-title":"Cell Host Microbe"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/v3081417","article-title":"Adenovirus recruits dynein by an evolutionary novel mechanism involving direct binding to pH-primed hexon","volume":"3","author":"Scherer","year":"2011","journal-title":"Viruses"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02889-14","article-title":"Conformational changes in the adenovirus hexon subunit responsible for regulating cytoplasmic dynein recruitment","volume":"89","author":"Scherer","year":"2015","journal-title":"J Virol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1089\/08828240050144671","article-title":"Immunoreactive domains and integrin-binding motifs in adenovirus penton base capsomer","volume":"13","author":"Hong","year":"2000","journal-title":"Viral Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.77.19.10366-10375.2003","article-title":"Identification of adenovirus (ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (addl1520) for treatment of liver tumors","volume":"77","author":"Hong","year":"2003","journal-title":"J Virol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2019.12.005","article-title":"A novel human monoclonal antibody potently neutralizes human adenovirus serotype 7 by primarily targeting the adenovirus hexon protein","volume":"543","author":"Lu","year":"2020","journal-title":"Virology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.22.12320-12332.2004","article-title":"Postentry neutralization of adenovirus type 5 by an antihexon antibody","volume":"78","author":"Varghese","year":"2004","journal-title":"J Virol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/0378-1097(92)90126-9","article-title":"Antibody-mediated uncoating of adenovirus in vitro","volume":"77","author":"Everitt","year":"1992","journal-title":"FEMS Microbiol Lett"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1995.9949","article-title":"Antigenic sites on the receptor-binding domain of human adenovirus type 2 fiber","volume":"214","author":"Fender","year":"1995","journal-title":"Virology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2019.00417","article-title":"A murine monoclonal antibody with potent neutralization ability against human adenovirus 7","volume":"9","author":"Wang","year":"2019","journal-title":"Front Cell Infect Microbiol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-277-9_17","article-title":"Large-Scale purification and crystallization of adenovirus hexon","volume":"131","author":"Rux","year":"2007","journal-title":"Methods Mol Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01587-20","article-title":"Structural basis for the shared neutralization mechanism of three classes of human papillomavirus type 58 antibodies with disparate modes of binding","volume":"95","author":"He","year":"2021","journal-title":"J Virol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/s0022-1759(96)00208-6","article-title":"Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system","volume":"201","author":"Krebber","year":"1997","journal-title":"J Immunol Methods"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02278","article-title":"Understanding the significance and implications of antibody numbering and antigen-binding Surface\/Residue definition","volume":"9","author":"Dondelinger","year":"2018","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2016.180","article-title":"Modeling and docking of antibody structures with Rosetta","volume":"12","author":"Weitzner","year":"2017","journal-title":"Nat Protoc"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.729513","article-title":"Structural biology in the clouds: The WeNMR-EOSC ecosystem","volume":"8","author":"Honorato","year":"2021","journal-title":"Front Mol Biosci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/antib11010010","article-title":"Construction of a humanized artificial VHH library reproducing structural features of camelid VHHs for therapeutics","volume":"11","author":"Murakami","year":"2022","journal-title":"Antibodies (Basel)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btab434","article-title":"Humanization of antibodies using a machine learning approach on large-scale repertoire data","volume":"37","author":"Marks","year":"2021","journal-title":"Bioinformatics"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.06254-11","article-title":"Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection","volume":"86","author":"Bradley","year":"2012","journal-title":"J Virol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2013.08.013","article-title":"Epitope mapping and characterization of a neutralizing monoclonal antibody against human adenovirus type 3","volume":"177","author":"Tian","year":"2013","journal-title":"Virus Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41426-018-0197-8","article-title":"Broadly neutralizing monoclonal antibodies against human adenovirus types 55, 14p, 7, and 11 generated with recombinant type 11 fiber knob","volume":"7","author":"Tian","year":"2018","journal-title":"Emerg Microbes Infect"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.3.2388-2397.1998","article-title":"Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity","volume":"72","author":"Gahery-Segard","year":"1998","journal-title":"J Virol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.11.7179","article-title":"Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein","volume":"174","author":"Sumida","year":"2005","journal-title":"J Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.06165-11","article-title":"Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions","volume":"86","author":"Bradley","year":"2012","journal-title":"J Virol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00866-09","article-title":"Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization","volume":"84","author":"Cheng","year":"2010","journal-title":"J Virol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1132822\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T05:32:13Z","timestamp":1678944733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1132822\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":43,"alternative-id":["10.3389\/fimmu.2023.1132822"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1132822","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,16]]},"article-number":"1132822"}}